COMETRIQ (nda203756)- (EQ 20MG BASE,EQ 80MG BASE)

Generic Name	CABOZANTINIB S-MALATE	Innovator	EXELIXIS
Dosage	EQ 20MG BASE,EQ 80MG BASE
ParaIV Filing	No	505(b)2 Filing	No
Last Patent Expiry	2032-Feb-10	NCE Excl Expiry	2017-Nov-29
ODE Expiry	2019-Nov-29	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	1

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
EQ 20MG BASE	**	**	-	-	-
EQ 80MG BASE	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of COMETRIQ